GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill joins fight against advanced stomach cancer in global trial
Disease control Recruiting nowThis global study is testing whether adding a new oral capsule called UTD2 to standard chemotherapy helps people with advanced stomach or gastroesophageal cancer live longer. It will involve about 778 adults who have not yet received drug treatment for their advanced cancer. The …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for tough cancers: first human trial of experimental drug begins
Disease control Recruiting nowThis is an early-stage study testing a new drug called Spevatamig (PT886) in people with advanced cancers of the stomach, pancreas, and bile ducts. The main goals are to find a safe dose and see how well the body handles the drug. It will be tested alone and in combination with s…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New drug trial targets tough stomach cancers after standard treatments fail
Disease control Recruiting nowThis study is testing an experimental drug called HLX43 for people with advanced stomach or gastroesophageal junction cancer that has continued to grow despite standard treatments. The trial aims to find a safe and effective dose while measuring how well the drug shrinks tumors a…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC